- Home
- ACP vs GERN Comparison
ACP vs GERN Comparison
Compare ACP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ACP | GERN |
|---|---|---|
| Founded | 2010 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 712.7M | 753.3M |
| IPO Year | N/A | 1996 |
Fundamental Metrics
Financial Performance| Metric | ACP | GERN |
|---|---|---|
| Price | $5.40 | $1.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 337.9K | ★ 6.9M |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | ★ 17.79% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $183,403,000.00 |
| Revenue This Year | N/A | $147.34 |
| Revenue Next Year | N/A | $39.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 522.13 |
| 52 Week Low | $5.55 | $1.04 |
| 52 Week High | $7.17 | $4.01 |
Technical Indicators
Market Signals| Indicator | ACP | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 44.58 | 60.64 |
| Support Level | $5.37 | $1.21 |
| Resistance Level | $5.48 | $1.42 |
| Average True Range (ATR) | 0.05 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 52.72 | 74.14 |
Price Performance
Historical ComparisonAbout ACP abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end management investment company. Its investment objective is to seek a high level of current income with a secondary objective of capital appreciation. It predominantly invests in debt and loan instruments of issues that operate in a variety of industries and geographic regions.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.